MovDisordV3, PascalFrancis, Corpus, bibRecord, 002822

Levodopa-induced dyskinesias and continuous subcutaneous infusions of apomorphine: Results of a two-year, prospective follow-up

Identifieur interne : 002822 ( PascalFrancis/Corpus ); précédent : 002821; suivant : 002823

Levodopa-induced dyskinesias and continuous subcutaneous infusions of apomorphine: Results of a two-year, prospective follow-up

Auteurs : Petr Kanovsky ; Dagmar Kubova ; Martin Bares ; Hana Hortova ; Hana Streitova ; Ivan Rektor ; Vladimir Znojil

Source :

Movement disorders [ 0885-3185 ] ; 2002.

RBID : Pascal:02-0206615

Descripteurs français

Pascal (Inist)
- Dyskinésie, Lévodopa, Chimiothérapie, Antiparkinsonien, Parkinson maladie, Dose faible, Apomorphine, Agoniste, Récepteur dopaminergique, Stimulant dopaminergique, Voie souscutanée, Continu, Traitement, Toxicité, Pronostic, Adulte, Fluctuation motrice.

English descriptors

KwdEn :
- Adult, Agonist, Antiparkinson agent, Chemotherapy, Continuous, Dopamine agonist, Dopamine receptor, Dyskinesia, Levodopa, Low dose, Parkinson disease, Prognosis, Subcutaneous administration, Toxicity, Treatment.

Abstract

Twelve patients with levodopa-induced dyskinesias were treated with continuous subcutaneous apomorphine. A markedly significant reduction in peak dose dyskinesias occurred over a two-year follow-up.

Notice en format standard (ISO 2709)

Pour connaître la documentation sur le format Inist Standard.

A01	`01`	`1`		`@0 0885-3185`
A03		`1`		`@0 Mov. disord.`
A05				`@2 17`
A06				`@2 1`
A08	`01`	`1`	`ENG`	`@1 Levodopa-induced dyskinesias and continuous subcutaneous infusions of apomorphine: Results of a two-year, prospective follow-up`
A11	`01`	`1`		`@1 KANOVSKY (Petr)`
A11	`02`	`1`		`@1 KUBOVA (Dagmar)`
A11	`03`	`1`		`@1 BARES (Martin)`
A11	`04`	`1`		`@1 HORTOVA (Hana)`
A11	`05`	`1`		`@1 STREITOVA (Hana)`
A11	`06`	`1`		`@1 REKTOR (Ivan)`
A11	`07`	`1`		`@1 ZNOJIL (Vladimir)`
A14	`01`			`@1 1st Department of Neurology, Masaryk University, St. Anne Hospital @2 Brno @3 CZE @Z 1 aut. @Z 2 aut. @Z 3 aut. @Z 4 aut. @Z 5 aut. @Z 6 aut.`
A14	`02`			`@1 Biostatistics Unit, Department of Experimental Pathology, Masaryk University @2 Brno @3 CZE @Z 7 aut.`
A20				`@1 188-191`
A21				`@1 2002`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 20953 @5 354000100147290310`
A44				`@0 0000 @1 © 2002 INIST-CNRS. All rights reserved.`
A45				`@0 36 ref.`
A47	`01`	`1`		`@0 02-0206615`
A60				`@1 P`
A61				`@0 A`
A64	`01`	`1`		`@0 Movement disorders`
A66	`01`			`@0 USA`
C01	`01`		`ENG`	`@0 Twelve patients with levodopa-induced dyskinesias were treated with continuous subcutaneous apomorphine. A markedly significant reduction in peak dose dyskinesias occurred over a two-year follow-up.`
C02	`01`	`X`		`@0 002B02U01`
C03	`01`	`X`	`FRE`	`@0 Dyskinésie @5 01`
C03	`01`	`X`	`ENG`	`@0 Dyskinesia @5 01`
C03	`01`	`X`	`SPA`	`@0 Disquinesia @5 01`
C03	`02`	`X`	`FRE`	`@0 Lévodopa @2 NK @2 FR @5 04`
C03	`02`	`X`	`ENG`	`@0 Levodopa @2 NK @2 FR @5 04`
C03	`02`	`X`	`SPA`	`@0 Levodopa @2 NK @2 FR @5 04`
C03	`03`	`X`	`FRE`	`@0 Chimiothérapie @5 05`
C03	`03`	`X`	`ENG`	`@0 Chemotherapy @5 05`
C03	`03`	`X`	`SPA`	`@0 Quimioterapia @5 05`
C03	`04`	`X`	`FRE`	`@0 Antiparkinsonien @5 06`
C03	`04`	`X`	`ENG`	`@0 Antiparkinson agent @5 06`
C03	`04`	`X`	`SPA`	`@0 Antiparkinsoniano @5 06`
C03	`05`	`X`	`FRE`	`@0 Parkinson maladie @5 07`
C03	`05`	`X`	`ENG`	`@0 Parkinson disease @5 07`
C03	`05`	`X`	`SPA`	`@0 Parkinson enfermedad @5 07`
C03	`06`	`X`	`FRE`	`@0 Dose faible @5 09`
C03	`06`	`X`	`ENG`	`@0 Low dose @5 09`
C03	`06`	`X`	`SPA`	`@0 Dosis débil @5 09`
C03	`07`	`X`	`FRE`	`@0 Apomorphine @2 NK @2 FR @5 10`
C03	`08`	`X`	`FRE`	`@0 Agoniste @5 11`
C03	`08`	`X`	`ENG`	`@0 Agonist @5 11`
C03	`08`	`X`	`SPA`	`@0 Agonista @5 11`
C03	`09`	`X`	`FRE`	`@0 Récepteur dopaminergique @5 12`
C03	`09`	`X`	`ENG`	`@0 Dopamine receptor @5 12`
C03	`09`	`X`	`SPA`	`@0 Receptor dopaminérgico @5 12`
C03	`10`	`X`	`FRE`	`@0 Stimulant dopaminergique @5 13`
C03	`10`	`X`	`ENG`	`@0 Dopamine agonist @5 13`
C03	`10`	`X`	`SPA`	`@0 Estimulante dopaminérgico @5 13`
C03	`11`	`X`	`FRE`	`@0 Voie souscutanée @5 14`
C03	`11`	`X`	`ENG`	`@0 Subcutaneous administration @5 14`
C03	`11`	`X`	`SPA`	`@0 Vía subcutánea @5 14`
C03	`12`	`X`	`FRE`	`@0 Continu @5 15`
C03	`12`	`X`	`ENG`	`@0 Continuous @5 15`
C03	`12`	`X`	`SPA`	`@0 Contínuo @5 15`
C03	`13`	`X`	`FRE`	`@0 Traitement @5 17`
C03	`13`	`X`	`ENG`	`@0 Treatment @5 17`
C03	`13`	`X`	`SPA`	`@0 Tratamiento @5 17`
C03	`14`	`X`	`FRE`	`@0 Toxicité @5 18`
C03	`14`	`X`	`ENG`	`@0 Toxicity @5 18`
C03	`14`	`X`	`SPA`	`@0 Toxicidad @5 18`
C03	`15`	`X`	`FRE`	`@0 Pronostic @5 19`
C03	`15`	`X`	`ENG`	`@0 Prognosis @5 19`
C03	`15`	`X`	`SPA`	`@0 Pronóstico @5 19`
C03	`16`	`X`	`FRE`	`@0 Adulte @5 20`
C03	`16`	`X`	`ENG`	`@0 Adult @5 20`
C03	`16`	`X`	`SPA`	`@0 Adulto @5 20`
C03	`17`	`X`	`FRE`	`@0 Fluctuation motrice @4 INC @5 86`
C07	`01`	`X`	`FRE`	`@0 Homme`
C07	`01`	`X`	`ENG`	`@0 Human`
C07	`01`	`X`	`SPA`	`@0 Hombre`
C07	`02`	`X`	`FRE`	`@0 Système nerveux pathologie @5 37`
C07	`02`	`X`	`ENG`	`@0 Nervous system diseases @5 37`
C07	`02`	`X`	`SPA`	`@0 Sistema nervioso patología @5 37`
C07	`03`	`X`	`FRE`	`@0 Trouble neurologique @5 38`
C07	`03`	`X`	`ENG`	`@0 Neurological disorder @5 38`
C07	`03`	`X`	`SPA`	`@0 Trastorno neurológico @5 38`
C07	`04`	`X`	`FRE`	`@0 Mouvement involontaire @5 39`
C07	`04`	`X`	`ENG`	`@0 Involuntary movement @5 39`
C07	`04`	`X`	`SPA`	`@0 Movimiento involuntario @5 39`
C07	`05`	`X`	`FRE`	`@0 Extrapyramidal syndrome @5 40`
C07	`05`	`X`	`ENG`	`@0 Extrapyramidal syndrome @5 40`
C07	`05`	`X`	`SPA`	`@0 Extrapiramidal síndrome @5 40`
C07	`06`	`X`	`FRE`	`@0 Système nerveux central pathologie @5 54`
C07	`06`	`X`	`ENG`	`@0 Central nervous system disease @5 54`
C07	`06`	`X`	`SPA`	`@0 Sistema nervosio central patología @5 54`
C07	`07`	`X`	`FRE`	`@0 Encéphale pathologie @5 55`
C07	`07`	`X`	`ENG`	`@0 Cerebral disorder @5 55`
C07	`07`	`X`	`SPA`	`@0 Encéfalo patología @5 55`
C07	`08`	`X`	`FRE`	`@0 Maladie dégénérative @5 57`
C07	`08`	`X`	`ENG`	`@0 Degenerative disease @5 57`
C07	`08`	`X`	`SPA`	`@0 Enfermedad degenerativa @5 57`
N21				`@1 119`
N82				`@1 PSI`

Format Inist (serveur)

NO :	PASCAL 02-0206615 INIST
ET :	Levodopa-induced dyskinesias and continuous subcutaneous infusions of apomorphine: Results of a two-year, prospective follow-up
AU :	KANOVSKY (Petr); KUBOVA (Dagmar); BARES (Martin); HORTOVA (Hana); STREITOVA (Hana); REKTOR (Ivan); ZNOJIL (Vladimir)
AF :	1st Department of Neurology, Masaryk University, St. Anne Hospital/Brno/Tchèque, République (1 aut., 2 aut., 3 aut., 4 aut., 5 aut., 6 aut.); Biostatistics Unit, Department of Experimental Pathology, Masaryk University/Brno/Tchèque, République (7 aut.)
DT :	Publication en série; Niveau analytique
SO :	Movement disorders; ISSN 0885-3185; Etats-Unis; Da. 2002; Vol. 17; No. 1; Pp. 188-191; Bibl. 36 ref.
LA :	Anglais
EA :	Twelve patients with levodopa-induced dyskinesias were treated with continuous subcutaneous apomorphine. A markedly significant reduction in peak dose dyskinesias occurred over a two-year follow-up.
CC :	002B02U01
FD :	Dyskinésie; Lévodopa; Chimiothérapie; Antiparkinsonien; Parkinson maladie; Dose faible; Apomorphine; Agoniste; Récepteur dopaminergique; Stimulant dopaminergique; Voie souscutanée; Continu; Traitement; Toxicité; Pronostic; Adulte; Fluctuation motrice
FG :	Homme; Système nerveux pathologie; Trouble neurologique; Mouvement involontaire; Extrapyramidal syndrome; Système nerveux central pathologie; Encéphale pathologie; Maladie dégénérative
ED :	Dyskinesia; Levodopa; Chemotherapy; Antiparkinson agent; Parkinson disease; Low dose; Agonist; Dopamine receptor; Dopamine agonist; Subcutaneous administration; Continuous; Treatment; Toxicity; Prognosis; Adult
EG :	Human; Nervous system diseases; Neurological disorder; Involuntary movement; Extrapyramidal syndrome; Central nervous system disease; Cerebral disorder; Degenerative disease
SD :	Disquinesia; Levodopa; Quimioterapia; Antiparkinsoniano; Parkinson enfermedad; Dosis débil; Agonista; Receptor dopaminérgico; Estimulante dopaminérgico; Vía subcutánea; Contínuo; Tratamiento; Toxicidad; Pronóstico; Adulto
LO :	INIST-20953.354000100147290310
ID :	02-0206615

Links to Exploration step

Pascal:02-0206615

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Levodopa-induced dyskinesias and continuous subcutaneous infusions of apomorphine: Results of a two-year, prospective follow-up</title>
<author><name sortKey="Kanovsky, Petr" sort="Kanovsky, Petr" uniqKey="Kanovsky P" first="Petr" last="Kanovsky">Petr Kanovsky</name>
<affiliation><inist:fA14 i1="01"><s1>1st Department of Neurology, Masaryk University, St. Anne Hospital</s1>
<s2>Brno</s2>
<s3>CZE</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Kubova, Dagmar" sort="Kubova, Dagmar" uniqKey="Kubova D" first="Dagmar" last="Kubova">Dagmar Kubova</name>
<affiliation><inist:fA14 i1="01"><s1>1st Department of Neurology, Masaryk University, St. Anne Hospital</s1>
<s2>Brno</s2>
<s3>CZE</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Bares, Martin" sort="Bares, Martin" uniqKey="Bares M" first="Martin" last="Bares">Martin Bares</name>
<affiliation><inist:fA14 i1="01"><s1>1st Department of Neurology, Masaryk University, St. Anne Hospital</s1>
<s2>Brno</s2>
<s3>CZE</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Hortova, Hana" sort="Hortova, Hana" uniqKey="Hortova H" first="Hana" last="Hortova">Hana Hortova</name>
<affiliation><inist:fA14 i1="01"><s1>1st Department of Neurology, Masaryk University, St. Anne Hospital</s1>
<s2>Brno</s2>
<s3>CZE</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Streitova, Hana" sort="Streitova, Hana" uniqKey="Streitova H" first="Hana" last="Streitova">Hana Streitova</name>
<affiliation><inist:fA14 i1="01"><s1>1st Department of Neurology, Masaryk University, St. Anne Hospital</s1>
<s2>Brno</s2>
<s3>CZE</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Rektor, Ivan" sort="Rektor, Ivan" uniqKey="Rektor I" first="Ivan" last="Rektor">Ivan Rektor</name>
<affiliation><inist:fA14 i1="01"><s1>1st Department of Neurology, Masaryk University, St. Anne Hospital</s1>
<s2>Brno</s2>
<s3>CZE</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Znojil, Vladimir" sort="Znojil, Vladimir" uniqKey="Znojil V" first="Vladimir" last="Znojil">Vladimir Znojil</name>
<affiliation><inist:fA14 i1="02"><s1>Biostatistics Unit, Department of Experimental Pathology, Masaryk University</s1>
<s2>Brno</s2>
<s3>CZE</s3>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">02-0206615</idno>
<date when="2002">2002</date>
<idno type="stanalyst">PASCAL 02-0206615 INIST</idno>
<idno type="RBID">Pascal:02-0206615</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">002822</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Levodopa-induced dyskinesias and continuous subcutaneous infusions of apomorphine: Results of a two-year, prospective follow-up</title>
<author><name sortKey="Kanovsky, Petr" sort="Kanovsky, Petr" uniqKey="Kanovsky P" first="Petr" last="Kanovsky">Petr Kanovsky</name>
<affiliation><inist:fA14 i1="01"><s1>1st Department of Neurology, Masaryk University, St. Anne Hospital</s1>
<s2>Brno</s2>
<s3>CZE</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Kubova, Dagmar" sort="Kubova, Dagmar" uniqKey="Kubova D" first="Dagmar" last="Kubova">Dagmar Kubova</name>
<affiliation><inist:fA14 i1="01"><s1>1st Department of Neurology, Masaryk University, St. Anne Hospital</s1>
<s2>Brno</s2>
<s3>CZE</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Bares, Martin" sort="Bares, Martin" uniqKey="Bares M" first="Martin" last="Bares">Martin Bares</name>
<affiliation><inist:fA14 i1="01"><s1>1st Department of Neurology, Masaryk University, St. Anne Hospital</s1>
<s2>Brno</s2>
<s3>CZE</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Hortova, Hana" sort="Hortova, Hana" uniqKey="Hortova H" first="Hana" last="Hortova">Hana Hortova</name>
<affiliation><inist:fA14 i1="01"><s1>1st Department of Neurology, Masaryk University, St. Anne Hospital</s1>
<s2>Brno</s2>
<s3>CZE</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Streitova, Hana" sort="Streitova, Hana" uniqKey="Streitova H" first="Hana" last="Streitova">Hana Streitova</name>
<affiliation><inist:fA14 i1="01"><s1>1st Department of Neurology, Masaryk University, St. Anne Hospital</s1>
<s2>Brno</s2>
<s3>CZE</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Rektor, Ivan" sort="Rektor, Ivan" uniqKey="Rektor I" first="Ivan" last="Rektor">Ivan Rektor</name>
<affiliation><inist:fA14 i1="01"><s1>1st Department of Neurology, Masaryk University, St. Anne Hospital</s1>
<s2>Brno</s2>
<s3>CZE</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Znojil, Vladimir" sort="Znojil, Vladimir" uniqKey="Znojil V" first="Vladimir" last="Znojil">Vladimir Znojil</name>
<affiliation><inist:fA14 i1="02"><s1>Biostatistics Unit, Department of Experimental Pathology, Masaryk University</s1>
<s2>Brno</s2>
<s3>CZE</s3>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
<imprint><date when="2002">2002</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term>
<term>Agonist</term>
<term>Antiparkinson agent</term>
<term>Chemotherapy</term>
<term>Continuous</term>
<term>Dopamine agonist</term>
<term>Dopamine receptor</term>
<term>Dyskinesia</term>
<term>Levodopa</term>
<term>Low dose</term>
<term>Parkinson disease</term>
<term>Prognosis</term>
<term>Subcutaneous administration</term>
<term>Toxicity</term>
<term>Treatment</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Dyskinésie</term>
<term>Lévodopa</term>
<term>Chimiothérapie</term>
<term>Antiparkinsonien</term>
<term>Parkinson maladie</term>
<term>Dose faible</term>
<term>Apomorphine</term>
<term>Agoniste</term>
<term>Récepteur dopaminergique</term>
<term>Stimulant dopaminergique</term>
<term>Voie souscutanée</term>
<term>Continu</term>
<term>Traitement</term>
<term>Toxicité</term>
<term>Pronostic</term>
<term>Adulte</term>
<term>Fluctuation motrice</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Twelve patients with levodopa-induced dyskinesias were treated with continuous subcutaneous apomorphine. A markedly significant reduction in peak dose dyskinesias occurred over a two-year follow-up.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0885-3185</s0>
</fA01>
<fA03 i2="1"><s0>Mov. disord.</s0>
</fA03>
<fA05><s2>17</s2>
</fA05>
<fA06><s2>1</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Levodopa-induced dyskinesias and continuous subcutaneous infusions of apomorphine: Results of a two-year, prospective follow-up</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>KANOVSKY (Petr)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>KUBOVA (Dagmar)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>BARES (Martin)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>HORTOVA (Hana)</s1>
</fA11>
<fA11 i1="05" i2="1"><s1>STREITOVA (Hana)</s1>
</fA11>
<fA11 i1="06" i2="1"><s1>REKTOR (Ivan)</s1>
</fA11>
<fA11 i1="07" i2="1"><s1>ZNOJIL (Vladimir)</s1>
</fA11>
<fA14 i1="01"><s1>1st Department of Neurology, Masaryk University, St. Anne Hospital</s1>
<s2>Brno</s2>
<s3>CZE</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>Biostatistics Unit, Department of Experimental Pathology, Masaryk University</s1>
<s2>Brno</s2>
<s3>CZE</s3>
<sZ>7 aut.</sZ>
</fA14>
<fA20><s1>188-191</s1>
</fA20>
<fA21><s1>2002</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>20953</s2>
<s5>354000100147290310</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2002 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>36 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>02-0206615</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Movement disorders</s0>
</fA64>
<fA66 i1="01"><s0>USA</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>Twelve patients with levodopa-induced dyskinesias were treated with continuous subcutaneous apomorphine. A markedly significant reduction in peak dose dyskinesias occurred over a two-year follow-up.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B02U01</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Dyskinésie</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Dyskinesia</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Disquinesia</s0>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Lévodopa</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>04</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Levodopa</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>04</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Levodopa</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>04</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Chimiothérapie</s0>
<s5>05</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Chemotherapy</s0>
<s5>05</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Quimioterapia</s0>
<s5>05</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Antiparkinsonien</s0>
<s5>06</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Antiparkinson agent</s0>
<s5>06</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Antiparkinsoniano</s0>
<s5>06</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Parkinson maladie</s0>
<s5>07</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Parkinson disease</s0>
<s5>07</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Parkinson enfermedad</s0>
<s5>07</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Dose faible</s0>
<s5>09</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Low dose</s0>
<s5>09</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Dosis débil</s0>
<s5>09</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>Apomorphine</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>10</s5>
</fC03>
<fC03 i1="08" i2="X" l="FRE"><s0>Agoniste</s0>
<s5>11</s5>
</fC03>
<fC03 i1="08" i2="X" l="ENG"><s0>Agonist</s0>
<s5>11</s5>
</fC03>
<fC03 i1="08" i2="X" l="SPA"><s0>Agonista</s0>
<s5>11</s5>
</fC03>
<fC03 i1="09" i2="X" l="FRE"><s0>Récepteur dopaminergique</s0>
<s5>12</s5>
</fC03>
<fC03 i1="09" i2="X" l="ENG"><s0>Dopamine receptor</s0>
<s5>12</s5>
</fC03>
<fC03 i1="09" i2="X" l="SPA"><s0>Receptor dopaminérgico</s0>
<s5>12</s5>
</fC03>
<fC03 i1="10" i2="X" l="FRE"><s0>Stimulant dopaminergique</s0>
<s5>13</s5>
</fC03>
<fC03 i1="10" i2="X" l="ENG"><s0>Dopamine agonist</s0>
<s5>13</s5>
</fC03>
<fC03 i1="10" i2="X" l="SPA"><s0>Estimulante dopaminérgico</s0>
<s5>13</s5>
</fC03>
<fC03 i1="11" i2="X" l="FRE"><s0>Voie souscutanée</s0>
<s5>14</s5>
</fC03>
<fC03 i1="11" i2="X" l="ENG"><s0>Subcutaneous administration</s0>
<s5>14</s5>
</fC03>
<fC03 i1="11" i2="X" l="SPA"><s0>Vía subcutánea</s0>
<s5>14</s5>
</fC03>
<fC03 i1="12" i2="X" l="FRE"><s0>Continu</s0>
<s5>15</s5>
</fC03>
<fC03 i1="12" i2="X" l="ENG"><s0>Continuous</s0>
<s5>15</s5>
</fC03>
<fC03 i1="12" i2="X" l="SPA"><s0>Contínuo</s0>
<s5>15</s5>
</fC03>
<fC03 i1="13" i2="X" l="FRE"><s0>Traitement</s0>
<s5>17</s5>
</fC03>
<fC03 i1="13" i2="X" l="ENG"><s0>Treatment</s0>
<s5>17</s5>
</fC03>
<fC03 i1="13" i2="X" l="SPA"><s0>Tratamiento</s0>
<s5>17</s5>
</fC03>
<fC03 i1="14" i2="X" l="FRE"><s0>Toxicité</s0>
<s5>18</s5>
</fC03>
<fC03 i1="14" i2="X" l="ENG"><s0>Toxicity</s0>
<s5>18</s5>
</fC03>
<fC03 i1="14" i2="X" l="SPA"><s0>Toxicidad</s0>
<s5>18</s5>
</fC03>
<fC03 i1="15" i2="X" l="FRE"><s0>Pronostic</s0>
<s5>19</s5>
</fC03>
<fC03 i1="15" i2="X" l="ENG"><s0>Prognosis</s0>
<s5>19</s5>
</fC03>
<fC03 i1="15" i2="X" l="SPA"><s0>Pronóstico</s0>
<s5>19</s5>
</fC03>
<fC03 i1="16" i2="X" l="FRE"><s0>Adulte</s0>
<s5>20</s5>
</fC03>
<fC03 i1="16" i2="X" l="ENG"><s0>Adult</s0>
<s5>20</s5>
</fC03>
<fC03 i1="16" i2="X" l="SPA"><s0>Adulto</s0>
<s5>20</s5>
</fC03>
<fC03 i1="17" i2="X" l="FRE"><s0>Fluctuation motrice</s0>
<s4>INC</s4>
<s5>86</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Homme</s0>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Human</s0>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Hombre</s0>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Système nerveux pathologie</s0>
<s5>37</s5>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Nervous system diseases</s0>
<s5>37</s5>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Sistema nervioso patología</s0>
<s5>37</s5>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Trouble neurologique</s0>
<s5>38</s5>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Neurological disorder</s0>
<s5>38</s5>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Trastorno neurológico</s0>
<s5>38</s5>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Mouvement involontaire</s0>
<s5>39</s5>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Involuntary movement</s0>
<s5>39</s5>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Movimiento involuntario</s0>
<s5>39</s5>
</fC07>
<fC07 i1="05" i2="X" l="FRE"><s0>Extrapyramidal syndrome</s0>
<s5>40</s5>
</fC07>
<fC07 i1="05" i2="X" l="ENG"><s0>Extrapyramidal syndrome</s0>
<s5>40</s5>
</fC07>
<fC07 i1="05" i2="X" l="SPA"><s0>Extrapiramidal síndrome</s0>
<s5>40</s5>
</fC07>
<fC07 i1="06" i2="X" l="FRE"><s0>Système nerveux central pathologie</s0>
<s5>54</s5>
</fC07>
<fC07 i1="06" i2="X" l="ENG"><s0>Central nervous system disease</s0>
<s5>54</s5>
</fC07>
<fC07 i1="06" i2="X" l="SPA"><s0>Sistema nervosio central patología</s0>
<s5>54</s5>
</fC07>
<fC07 i1="07" i2="X" l="FRE"><s0>Encéphale pathologie</s0>
<s5>55</s5>
</fC07>
<fC07 i1="07" i2="X" l="ENG"><s0>Cerebral disorder</s0>
<s5>55</s5>
</fC07>
<fC07 i1="07" i2="X" l="SPA"><s0>Encéfalo patología</s0>
<s5>55</s5>
</fC07>
<fC07 i1="08" i2="X" l="FRE"><s0>Maladie dégénérative</s0>
<s5>57</s5>
</fC07>
<fC07 i1="08" i2="X" l="ENG"><s0>Degenerative disease</s0>
<s5>57</s5>
</fC07>
<fC07 i1="08" i2="X" l="SPA"><s0>Enfermedad degenerativa</s0>
<s5>57</s5>
</fC07>
<fN21><s1>119</s1>
</fN21>
<fN82><s1>PSI</s1>
</fN82>
</pA>
</standard>
<server><NO>PASCAL 02-0206615 INIST</NO>
<ET>Levodopa-induced dyskinesias and continuous subcutaneous infusions of apomorphine: Results of a two-year, prospective follow-up</ET>
<AU>KANOVSKY (Petr); KUBOVA (Dagmar); BARES (Martin); HORTOVA (Hana); STREITOVA (Hana); REKTOR (Ivan); ZNOJIL (Vladimir)</AU>
<AF>1st Department of Neurology, Masaryk University, St. Anne Hospital/Brno/Tchèque, République (1 aut., 2 aut., 3 aut., 4 aut., 5 aut., 6 aut.); Biostatistics Unit, Department of Experimental Pathology, Masaryk University/Brno/Tchèque, République (7 aut.)</AF>
<DT>Publication en série; Niveau analytique</DT>
<SO>Movement disorders; ISSN 0885-3185; Etats-Unis; Da. 2002; Vol. 17; No. 1; Pp. 188-191; Bibl. 36 ref.</SO>
<LA>Anglais</LA>
<EA>Twelve patients with levodopa-induced dyskinesias were treated with continuous subcutaneous apomorphine. A markedly significant reduction in peak dose dyskinesias occurred over a two-year follow-up.</EA>
<CC>002B02U01</CC>
<FD>Dyskinésie; Lévodopa; Chimiothérapie; Antiparkinsonien; Parkinson maladie; Dose faible; Apomorphine; Agoniste; Récepteur dopaminergique; Stimulant dopaminergique; Voie souscutanée; Continu; Traitement; Toxicité; Pronostic; Adulte; Fluctuation motrice</FD>
<FG>Homme; Système nerveux pathologie; Trouble neurologique; Mouvement involontaire; Extrapyramidal syndrome; Système nerveux central pathologie; Encéphale pathologie; Maladie dégénérative</FG>
<ED>Dyskinesia; Levodopa; Chemotherapy; Antiparkinson agent; Parkinson disease; Low dose; Agonist; Dopamine receptor; Dopamine agonist; Subcutaneous administration; Continuous; Treatment; Toxicity; Prognosis; Adult</ED>
<EG>Human; Nervous system diseases; Neurological disorder; Involuntary movement; Extrapyramidal syndrome; Central nervous system disease; Cerebral disorder; Degenerative disease</EG>
<SD>Disquinesia; Levodopa; Quimioterapia; Antiparkinsoniano; Parkinson enfermedad; Dosis débil; Agonista; Receptor dopaminérgico; Estimulante dopaminérgico; Vía subcutánea; Contínuo; Tratamiento; Toxicidad; Pronóstico; Adulto</SD>
<LO>INIST-20953.354000100147290310</LO>
<ID>02-0206615</ID>
</server>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PascalFrancis/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002822 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 002822 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    PascalFrancis
   |étape=   Corpus
   |type=    RBID
   |clé=     Pascal:02-0206615
   |texte=   Levodopa-induced dyskinesias and continuous subcutaneous infusions of apomorphine: Results of a two-year, prospective follow-up
}}

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024

	Movement Disorders (revue)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Movement Disorders (revue)

Levodopa-induced dyskinesias and continuous subcutaneous infusions of apomorphine: Results of a two-year, prospective follow-up

Levodopa-induced dyskinesias and continuous subcutaneous infusions of apomorphine: Results of a two-year, prospective follow-up

Source :

Descripteurs français

English descriptors

Abstract

Notice en format standard (ISO 2709)

Format Inist (serveur)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri